Clinical case: Nivolumab in 3rd line treatment of gastric cancer

Abstract

Gastric cancer still occupies a high place in the world in the structure of morbidity and mortality. In most patients, stomach cancer is locally advanced or metastatic, and therefore the 5-year overall survival rate does not exceed 35 %. The reason is the lack of clinical symptoms at the stage of the localized process and screening in the Russian Federation. The introduction of immunotherapy into clinical practice has radically changed approaches to the treatment of metastatic gastric cancer, which has increased the duration and quality of life of patients. According to the clinical recommendations of gastric cancer used in the third and subsequent lines of treatment, patients in satisfactory general condition are shown to use nivolumab immunotherapy in order to improve patient survival. Nivolumab (regardless of PD-L1 level) has shown excellent overall survival in most studies. The article describes a clinical case of Nivolumab treatment in a patient with disseminated gastric cancer in 3 lines. The article reflects the results of treatment and examination, evaluates the  effectiveness of treatment and makes a conclusion. The article is illustrated with original CT scans.